- Telehealth Visits
- Insurance plan information
Madhav R. Seshadri, MD
He | Him | HisMedical Oncology • Hematology- Telehealth Visits
- Insurance plan information
Madhav R. Seshadri, MD
He | Him | HisMedical Oncology • Hematology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Madhav R. Seshadri is a hematologist-oncologist who specializes in caring for patients with blood cancers, with a particular focus on Hodgkin's lymphoma, non-Hodgkin's lymphoma and chronic lymphocytic leukemia. He has expertise in advanced cancer treatments, such as stem cell transplants, targeted therapies (using substances that can identify cancer cells and kill them or hinder their ability to spread) and immunotherapies, including CAR T-cell therapy (in which the patient's own T-cells are altered in a lab to make them destroy cancer cells, then returned to the patient by infusion).
In his research, Seshadri focuses on developing new combinations of immunotherapy and targeted therapies to improve outcomes for patients with lymphoma. He is a principal investigator of multiple ongoing clinical trials (studies that use human volunteers to evaluate promising treatments) and has received several awards for his work.
Seshadri earned his medical degree at Emory University. He completed a residency in internal medicine and a fellowship in hematology and oncology at Weill Cornell Medicine.
In addition to his work at UCSF, Seshadri currently serves on the National Comprehensive Cancer Network's guidelines panel for chronic lymphocytic leukemia.
Education & training
Board certification
- Hematology, American Board of Internal Medicine/Hematology
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Hematology - Oncology, New York Presbyterian Hospital - Weill Cornell
Residency
- Internal Medicine, New York Presbyterian Hospital - Weill Cornell
Internship
- Internal Medicine, New York Presbyterian Hospital - Weill Cornell
Degree
- MD, Emory University School of Medicine
Academic title
- Health Sciences Clinical Professor
My expertise
Specialties
Locations
My research
Clinical trials
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaOpens in a new window
Recruiting
Will compare PFS in participants with relapsed/refractory large B-cell lymphoma or follicular lymphoma grade 3B with stable disease (SD) or partial remission (...Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaOpens in a new window
Recruiting
The severity of the toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (...
Publications
Showing 1-6 of 55 reviews
- April 29, 20265 out of 5 Stars
Dr. Seshadri was excellent in reviewing my situation and future actions. Superb. I trust his judgment.
- April 24, 20265 out of 5 Stars
Excellent experience
- April 21, 20265 out of 5 Stars
Couldn't be better. Excellent person and excellent doctor.
- April 5, 20265 out of 5 Stars
I am very grateful for Dr Seshadri. He carefully assessed and explained my situation. He discussed and answered questions about my current and future options.
- February 16, 20265 out of 5 Stars
Really very impressed with Dr's comprehensive knowledge and ability to answer my many questions.
- February 14, 20264.9 out of 5 Stars
It's not very likely that I'll have an opportunity to recommend Dr. Seshadri to anyone, I don't know a lot of people with CLL
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.